SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

6990

CNE1000062J1

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:28 2024-05-24 am EDT			5-day change	1st Jan Change
175.9 ^HKD	+0.92%		+3.05%	+70.94%

May. 24	Sichuan Kelun-biotech Biopharmaceutical to Present Its Cancer Drug Phase 3 Study Results at ASCO	MT
May. 24	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Results for Core Product Sacituzumab Tirumotecan(Sac-Tmt) At 2024 Asco Annual Meeting	CI

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.(SEHK:6990) added to S&P Global BMI Index

December 18, 2023 at 12:00 am EST

Latest news about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-biotech Biopharmaceutical to Present Its Cancer Drug Phase 3 Study Results at ASCO	May. 23	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Results for Core Product Sacituzumab Tirumotecan(Sac-Tmt) At 2024 Asco Annual Meeting	May. 23	CI
Sichuan Kelun-biotech Biopharmaceutical to Place 3.6 Million Shares; Inks Subscription Deal for 4.4 Million Shares	May. 07	MT
Kelun-Biotech's Lung Cancer Drug Advances to Phase 2 Trials in US; Shares Up 8%	May. 06	MT
Sichuan Kelun-Biotech Buys Structured Deposits Worth 680 Million Yuan	Apr. 15	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Study Results for Core Product Scituzumab Turumotecan (SAC-TMT) at AACR Annual Meeting 2024	Apr. 07	CI
Kelun-Biotech Shrinks Loss by 7% in 2023	Mar. 26	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
China Healthcare Stocks Rally on Hopes for Government Support	Mar. 14	DJ
China Grants Breakthrough Therapy Designation for Kelun-Biotech's Breast Cancer Treatment	Mar. 13	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Its Core Product SKB264 (MK-2870) Granted Breakthrough Therapy Designation for First-Line Treatment of Unresectable Locally Advanced, Recurring or Metastatic Pd-L1 Negative Tnbc by the National Medical Products Administration	Mar. 13	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Key Product A400 Granted Fast Track Designation by the US Food and Drug Administration	Mar. 11	CI
Kelun-Biotech Shares Start Trading in Shanghai's Southbound Stock Connect	Mar. 04	MT
Kelun-Biotech Licensee Starts Phase 3 Trials for Cancer Treatment; Shares Rise 5%	Feb. 23	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Collaboration with Merck Sharp & Dohme LLC	Feb. 22	CI
Kelun-Biotech Chosen as Constituent Stock of Hang Seng Indexes; Shares Fall 3%	Feb. 18	MT
Kelun-Biotech Controlling Shareholder Ups Stake; Shares Rise 4%	Jan. 22	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.(SEHK:6990) added to S&P Global BMI Index	Dec. 18	CI
China Accepts Kelun-Biotech's Application for Triple-Negative Breast Cancer Treatment; Shares Fall 4%	Dec. 11	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces New Drug Application for Core Product SKB264 (MK-2870) Accepts by the National Medical Products Administration	Dec. 10	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to Present the Updated Efficacy and Safety Results from Core Product	Nov. 30	CI
US FDA Grants Orphan Drug Designation for Kelun-Biotech's Solid Tumor Drug	Nov. 26	MT
Sichuan Kelun-Biotech Completes H Share Conversion	Nov. 24	MT
HKEX Permits Kelun Biotech to List H Shares	Nov. 17	MT
Kelun-Biotech Biopharma Gets Filing Notice for H Share Full Circulation	Nov. 14	MT

Chart Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Duration

Period

Chart Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

More charts

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, formerly Sichuan Kelun Biotech Biopharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production, and sales of drugs. The Company is mainly engaged in the research and development, production, and sales of biopharmaceuticals, chemical raw materials, and chemical drug formulations. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

175.9 HKD

Average target price

191.6 HKD

Spread / Average Target

+8.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+70.94%	5.02B
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs